Amitriptyline hydrochloride tablets for relief of depression symptoms

Amitriptyline hydrochloride tablets are prescription antidepressants used primarily to relieve symptoms of depression. They belong to a class of drugs known as tricyclic antidepressants and work by affecting neurotransmitters in the brain. These tablets come in multiple strengths and are intended for oral use in adults.

Approved use: Amitriptyline hydrochloride tablets are indicated for the relief of symptoms of depression, with a greater likelihood of efficacy in endogenous depression compared to other depressive states. This medication is for use in adult patients; it is not approved for pediatric patients under 12 years of age.

Amitriptyline hydrochloride

Amitriptyline hydrochloride acts by inhibiting the reuptake of norepinephrine and serotonin in nerve cells, which increases the levels of these neurotransmitters in the brain. This potentiation of neuronal activity is believed to help alleviate depressive symptoms. The exact mechanism for its antidepressant effects is not fully understood, but it is distinct from monoamine oxidase inhibitors and does not primarily stimulate the central nervous system.

Amitriptyline hydrochloride tablets are available in 10, 25, 50, 75, 100, and 150 mg strengths and are taken orally. Dosage should be individualized, typically starting at lower doses and gradually increased to achieve optimal therapeutic response while minimizing side effects. In elderly patients, dosing should begin cautiously at the low end of the range due to increased sensitivity and comorbidities.

If amitriptyline is being initiated after discontinuing a monoamine oxidase inhibitor (MAOI), at least 14 days should elapse before starting amitriptyline. Dose adjustments should be made based on clinical response.

Patients should use the smallest quantity of tablets necessary consistent with good patient management to reduce the risk of overdose.

Amitriptyline hydrochloride tablets are contraindicated in patients with known hypersensitivity to amitriptyline. They should not be administered concomitantly with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOIs. The drug is contraindicated with cisapride due to risk of QT prolongation and arrhythmia. It is also not recommended during the acute recovery phase following myocardial infarction.

Suicide risk: Antidepressants, including amitriptyline, can increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (up to 24 years) during the early treatment period. Close monitoring is essential during the first few months and when doses are changed. This medication is not approved for use in pediatric patients.

Serotonin syndrome: Potentially life-threatening serotonin syndrome can occur, especially when combined with other serotonergic drugs (SSRIs, SNRIs, triptans, lithium, tramadol, MAOIs, etc.). Symptoms include mental status changes, autonomic instability, neuromuscular dysfunction, seizures, and gastrointestinal symptoms. Concomitant use with MAOIs is contraindicated.

Bipolar disorder screening: Patients should be screened for bipolar disorder before starting treatment, as antidepressants may precipitate mania or hypomania.

Cardiovascular: Use cautiously in patients with cardiovascular disease due to risks of arrhythmias, tachycardia, and conduction abnormalities.

Glaucoma: Amitriptyline can cause pupil dilation and may trigger angle-closure glaucoma in susceptible individuals.

Hyponatremia: Cases related to SIADH have been reported; symptoms include headache, confusion, weakness, seizures, and potentially death, especially in the elderly and volume-depleted patients.

Other: Use caution in patients with history of seizures, urinary retention, or hepatic impairment; avoid use in acute recovery after myocardial infarction; monitor patients on thyroid medications closely.

Common side effects: Anticholinergic effects such as dry mouth, constipation, urinary retention, blurred vision, and tachycardia; sedation; dizziness; weight changes; and cognitive impairment.

Serious side effects: Arrhythmias, seizures, serotonin syndrome, worsening depression or emergent suicidality, angle-closure glaucoma, hyponatremia, and increased risk of falls in elderly patients.

Monoamine oxidase inhibitors (MAOIs): Concurrent use is contraindicated due to risk of severe reactions including hyperpyretic crisis and death; allow at least 14 days after stopping an MAOI before starting amitriptyline.

CYP2D6 inhibitors and poor metabolizers: Drugs that inhibit cytochrome P450 2D6 (e.g., SSRIs like fluoxetine, paroxetine, sertraline; quinidine; cimetidine; some antiarrhythmics) can increase amitriptyline levels, potentially causing toxicity. Dose adjustment and monitoring plasma levels may be necessary.

Serotonergic drugs: Increased risk of serotonin syndrome when used with SSRIs, SNRIs, triptans, lithium, tramadol, buspirone, tryptophan, St. John's Wort, fentanyl, and others.

Anticholinergic agents and sympathomimetics: Use with caution; close monitoring needed for potentiated effects and possible hyperpyrexia.

Alcohol, barbiturates, and CNS depressants: May enhance sedative effects of amitriptyline.

Pregnancy: Amitriptyline crosses the placenta. Animal studies have shown teratogenic effects at high doses, and sporadic reports suggest possible adverse fetal effects. Use during pregnancy is recommended only if the potential benefit justifies the potential risk to the fetus.

Lactation: Amitriptyline is excreted into breast milk. Although infant serum levels are usually undetectable, serious adverse reactions in nursing infants are possible. A decision should be made whether to discontinue nursing or the drug, weighing the importance to the mother.